GTC Biotherapeutics, Ovation to collaborate over anti-coagulant

06/24/2008 | Forbes · Reuters

GTC Biotherapeutics has entered into a deal worth up to $257 million with Ovation Pharmaceuticals to develop and market ATryn, an experimental treatment for hereditary anti-thrombin deficiency, in the U.S. GTC could receive up to $9 million in milestone payments upon approval of the drug, which has obtained orphan designation and fast-track status from the FDA.

View Full Article in:

Forbes · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY